Literature DB >> 10729170

Naturally occurring TAP-dependent specific T-cell tolerance for a variant of an immunodominant retroviral cytotoxic T-lymphocyte epitope.

V Kim1, J W Yewdell, W R Green.   

Abstract

Upon immunization and restimulation with tumors induced by the endogenous AKR/Gross murine leukemia virus (MuLV), C57BL/6 mice generate vigorous H-2K(b)-restricted cytotoxic T-lymphocyte (CTL) responses to a determinant (KSPWFTTL) derived from the p15E transmembrane portion of the viral envelope glycoprotein. By contrast, the highly homologous determinant RSPWFTTL, expressed by tumor cells induced by Friend/Moloney/Rauscher (FMR) MuLV, is not immunogenic, even when presented to the immune system as vaccinia virus-encoded cytosolic or endoplasmic reticulum (ER)-targeted minigene products. Such minigene products are usually highly immunogenic since they bypass the need for cells to liberate the peptide or transport the peptide into the ER by the transporter associated with antigen processing (TAP). Using KSPWFTTL-specific CTLs that cross-react with RSPWFTTL, we previously demonstrated that presentation of RSPWFTTL from its natural viral gene product is TAP dependent. Here, we show first that C57BL/6 mice express mRNA encoding RSPWFTTL but not KSPWFTTL and second that the ER-targeted RSPWFTTL minigene product is highly immunogenic in C57BL/6 mice with a targeted deletion in TAP1. These findings provide the initial demonstration of TAP-dependent tolerance induction to a specific self peptide and demonstrate that this contributes to the differential recognition of RSPWFTTL and KSPWFTTL by C57BL/6 mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729170      PMCID: PMC111904          DOI: 10.1128/jvi.74.8.3924-3928.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells.

Authors:  L Van Kaer; P G Ashton-Rickardt; H L Ploegh; S Tonegawa
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

2.  Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences.

Authors:  A Neisig; J Roelse; A J Sijts; F Ossendorp; M C Feltkamp; W M Kast; C J Melief; J J Neefjes
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

Review 3.  MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.

Authors:  R N Germain
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

Review 4.  Selective events in T cell development.

Authors:  E Robey; B J Fowlkes
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Origins of enhancer sequences of recombinant murine leukemia viruses from spontaneous B- and T-cell lymphomas of CWD mice.

Authors:  A C Massey; S C Lawrenz-Smith; D J Innes; C Y Thomas
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes.

Authors:  A J Sijts; F Ossendorp; E A Mengedé; P J van den Elsen; C J Melief
Journal:  J Immunol       Date:  1994-01-01       Impact factor: 5.422

7.  Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice.

Authors:  C J Aldrich; H G Ljunggren; L Van Kaer; P G Ashton-Rickardt; S Tonegawa; J Forman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.

Authors:  H D White; D A Roeder; W R Green
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

9.  Cytotoxic T lymphocyte responses to the envelope proteins of endogenous ecotropic and mink cytopathic focus-forming murine leukemia viruses in H-2b mice.

Authors:  M A Coppola; W R Green
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

10.  Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein.

Authors:  I Couillin; B Culmann-Penciolelli; E Gomard; J Choppin; J P Levy; J G Guillet; S Saragosti
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  4 in total

1.  Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation.

Authors:  Jennifer M Bomberger; Kenneth H Ely; Naveen Bangia; Siying Ye; Kathy A Green; William R Green; Richard I Enelow; Bruce A Stanton
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

2.  Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens.

Authors:  W Chen; C C Norbury; Y Cho; J W Yewdell; J R Bennink
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

3.  Endogenously Expressed Antigens Bind Mammalian RNA via Cationic Domains that Enhance Priming of Effector CD8 T Cells by DNA Vaccination.

Authors:  Jana Krieger; Petra Riedl; Katja Stifter; Gleyder Roman-Sosa; Thomas Seufferlein; Martin Wagner; Reinhold Schirmbeck
Journal:  Mol Ther       Date:  2019-01-22       Impact factor: 11.454

4.  IFN-γ treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.

Authors:  Katja Stifter; Jana Krieger; Leonie Ruths; Johann Gout; Medhanie Mulaw; Andre Lechel; Alexander Kleger; Thomas Seufferlein; Martin Wagner; Reinhold Schirmbeck
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.